To improve the safety of autotransplantation for myeloma, peripheral blood stem cell (PBSC) collection was attempted in 75 previously treated patients after the administration of high-dose cyclophosphamide (HD-CTX; 6 g/m2) with or without granulocyte-macrophage colony-stimulating factor (GM-CSF). Sixty patients subsequently received melphalan 200 mg/m2 (57 patients) or melphalan 140 mg/m2 and total body irradiation (850 cGy) (3 patients) supported by both autologous bone marrow and PBSC; 38 patients received GM-CSF posttransplantation. Among 72 patients undergoing PBSC apheresis, "good" mobilization (>50 colony-forming units granulocyte-macrophage [CFU-GM] per lo5 mononuclear cells) was achieved when prior chemotherapy did not exceed 1 year and when GM-CSF was used post-HD-CTX; similarly, rapid platelet recovery t o 50,00O/pL within 2 weeks was associated with " g o o d PBSC mobilization. These same variables also predicted for rapid engraftment after autotransplantation, so that hematologic recovery (granulo-ULTIPLE MYELOMA (MM) afflicts an elderly M patient population with a median age of about 65 years.' The addition of other alkylating agents and of doxorubicin to the standard melphalan-prednisone regimen has not extended median survival duration beyond 3 years.2 Recent data suggest that the clinical benefit from usually mildly myelosuppressive therapies may largely be due to glucocorticoids, which are an integral component of most standard dose regimens3 For chemotherapy of systemic malignancies to be curative, complete remissions (CRs) must be achieved in a sizeable fraction of patients. Melphalan-prednisone or similar regimens and even VAD treatment (vincristine-doxorubicin-dexamethasone) effect complete responses in only 10% to 15% of newly diagnosed patients with MM, usually with low tumor stage.4 Recently, dose intensity of chemotherapy has been increased to marrow-ablative levels requiring a u t o l o g o~s~-~~ or allogeneic hematopoietic stem cell support.13 Results indicated CR rates in the 30% to 50% range, depending on resistance to standard regimens and tumor mass. When applied for response consolidation, remissions of several years' duration have been reported.14 cytes >500/pL and platelets >50,000/ pL) proceeded within 2 weeks among the 37 patients with "good" PBSC collection.
M patient population with a median age of about 65 years. ' The addition of other alkylating agents and of doxorubicin to the standard melphalan-prednisone regimen has not extended median survival duration beyond 3 years.2 Recent data suggest that the clinical benefit from usually mildly myelosuppressive therapies may largely be due to glucocorticoids, which are an integral component of most standard dose regimens3 For chemotherapy of systemic malignancies to be curative, complete remissions (CRs) must be achieved in a sizeable fraction of patients. Melphalan-prednisone or similar regimens and even VAD treatment (vincristine-doxorubicin-dexamethasone) effect complete responses in only 10% to 15% of newly diagnosed patients with MM, usually with low tumor stage. 4 Recently, dose intensity of chemotherapy has been increased to marrow-ablative levels requiring a u t o l o g o~s~-~~ or allogeneic hematopoietic stem cell support.13 Results indicated CR rates in the 30% to 50% range, depending on resistance to standard regimens and tumor mass. When applied for response consolidation, remissions of several years' duration have been reported.14 cytes >500/pL and platelets >50,000/ pL) proceeded within 2 weeks among the 37 patients with "good" PBSC collection. As a result of rapid neutrophil recovery (>500/pL) within a median of 2 weeks, infectious complications both post-HD-CTX and posttransplant were readily manageable, resulting in only one treatment-related death post-HD-CTX. The cumulative response rate (275% cytoreduction) for all 75 patients was 68%, with 12-month event-free and overall survival projections of about 85%. Using both bone marrow and PBSC together with GM-CSF, autotransplants are safe and appear effective in myeloma, especially when prior therapy had been limited to less than 1 year. More than 80% of transplanted patients achieved complete hematologic recovery within a median of 1 month posttransplant (granulocytes >1,5OO/pL; platelets >lOO,OOO/pL; hemoglobin >10 g%), thus providing sufficient hematopoietic reserve for further chemotherapy in the event of posttransplant relapse. 0 1992 by The American Society of Hematology.
Allogeneic transplantation would appear to be the treatment of choice for any bone marrow (BM)-derived malignancy. However, limited matched sibling donor availability and high procedure-related morbidity and mortality among patients over age 55 favor autologous stem cell support for the majority of MM patients receiving intensive therapy.15
Life-threatening complications relate directly to the duration of BM aplasia. Recent studies by Gianni et a1 indicate accelerated hematopoietic engraftment through the combined use of BM and blood stem cells; granulocytemacrophage colony-stimulating factor (GM-CSF) was used (together with high-dose cyclophosphamide [HD-CTX]) for blood stem cell mobilization and again after transplantation.16 In previously untreated patients with malignant lymphoma receiving melphalan and total body irradiation (TBI), the duration of potentially life-threatening marrow aplasia was shortened to a few days.I6
This report summarizes our experience in procuring blood stem cells from patients with MM, as part of a program exploring double transplantation to achieve greater tumor cytoreduction and hence better long-term disease control. Blood stem cell mobilization with HD-CTX was impaired when prior treatment exposure exceeded 12 months and GM-CSF was not used. In the presence of adequate marrow and blood stem cells and with GM-CSF, rapid and complete hematopoietic recovery was assured after the administration of intravenous melphalan at 200 mg/m2.
MATERIALS AND METHODS
Between January 1990 and April 1991, 75 previously treated patients with symptomatic MM (Southwest Oncology Group Criteria) referred to the University of Arkansas for Medical Sciences received HD-CTX. Eligibility criteria included age I 70 years and performance status 5 2 (ECOG), and no organ compromise. All patients signed an informed consent to participate in the study as approved by the Institutional Review Board.
Patients' characteristics are shown in chemotherapy was 17 months (range, 3 to 79). One-third of patients had high tumor mass at diagnosis, 28% had elevated p-2-microglobulin (P2M) greater than 3 mg/L before HD-CTX, and 41% had MM that was resistant both to standard alkylating agents such as melphalan-prednisone and to VAD.
Intravenous hydration was initiated 12 hours before chemotherapy and maintained until 24 hours after completion of the last dose of CTX. HD-CTX 6 g/m2 was administered in five equally divided doses of 1.2 g/m2 over 1 hour each every 3 hours. Mesna 4.5 g/m2 was administered as a 24-hour continuous infusion starting together with the first dose of CTX. Intravenous furosemide was administered periodically to maintain an hourly urine output of greater than 100 mL during the first 24 hours after the initiation of HD-CTX chemotherapy.
Upon recovery of leukocytes to 800/pL and of platelets to at least 60,00O/pL, a double lumen Quinton catheter (Quinton Instrument Co, Seattle, WA) was inserted into a subclavian vein and apheresis was initiated. Awhite blood cell (WBC) count greater than 800ipL provided better cell yield at the initiation of apheresis; a platelet count greater than 60,000/ pL assured against bleeding complications during Quinton catheter placement and allowed for daily stem cell aphereses without platelet support. Fenwal CS3000 (Baxter Health Care Corp, Deerfield, IL) or Cobe Spectra (Cobe Laboratories Inc, Lakewood, CO) blood cell separators were used for stem cell separation. Stem cell collection was performed daily to obtain about 6 x lo8 mononuclear cells (MNC)/kg body weight (bw) to potentially support two cycles of marrow-ablative therapy.
Patients had diagnostic BM aspiration and biopsy before HD-CTX and after completion of PBSC collection. If marrow plasmacytosis was less than 30%, autologous BM was collected by multiple needle aspirations from posterior iliac crests under general anesthesia. Attempts were made to collect at least 3 x lo8 MNC/kg bw to rescue two cycles of high-dose therapy together with PBSC. Patients with marrow plasmacytosis greater than 30% undenvent extended blood stem cell harvest to procure 2 12 x lo8 MNC/kg bw.
The in vitro assay for granulocyte-macrophage colony-forming units (CFU-GM) was performed daily on all stem cell products from all patients. Briefly, 105 light-density cells from apheresis products were cultured in a base mixture of 0.8% methyl cellulose (Fisher Scientific, Pittsburgh, PA) containing Iscove's modified Dulbecco's medium, 10% heatinactivated fetal bovine serum, 1% deionized bovine serum albumin (Sigma, St Louis, MO), and 100 U of human recombinant GM-CSF (Amgen, Thousand Oaks, CA) in a total volume of 1 mL in 35-mm plates (Falcon, Lincoln Park, NJ). The plates were incubated in a humidified atmosphere of 5% CO2, 10% 0 2 , and 88%N2 at 37°C. Colonies were scored using an inverted microscope (Nikon, Tokyo, Japan) on day 14. Assays were performed in triplicates.
In addition, cells expressing CD34 antigen were identified by direct immunofluorescence with fluorescein isothiocyanate (FITC)-
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conjugated anti-CD34 murine monoclonal antibody ( M A C , Inc, Westbrook, ME), as previously reported."
Pretransplant cytoreduction consisted of melphalan 200 mg/m2 (MEL-200) administered in two equally divided doses on days -3 and -2 (54 patients), or of melphalan 140 mg/m2 on day -4 and TBI (850 cGy in 5 fractions on days -3 to -1) (MEL-TBI). Previously harvested autologous BM was reinfused on day 0. PBSC were equally split and reinfused on days 0 and + 1 to avoid daily infusion of more than 500 mL of stem cell product containing dimethylsulfoxide (DMSO) and red blood cells. Patients were nursed in a private room as part of a designated transplant unit. Antibiotic prophylaxis included daily oral ciprofloxacin 1 g and penicillin VK 1 g, while acyclovir 15 mg/kg was administered intravenously. In addition, Ig was intravenously on day -1 and day +14 at a dose of 500 mg/kg.
Upon availability of GM-CSF, the 39 recent patients received this growth factor subcutaneously at a dose of 250 pg/m2 starting 1 day after HD-CTX. GM-CSF was discontinued upon completion of apheresis or when WBC exceeded 30,00O/pL or when platelets had not recovered to at least 25,0001t~L by day 30 after HD-CTX.
Likewise, after transplantation, the 35 patients (of 60 total) who had more recently received transplants received GM-CSF starting on day +1 at a dose of 250 pg/m2. The dose was reduced by 50% when the absolute neutrophil count (ANC) reached 2,Doo/pL and discontinued when such level was sustained for 3 days. If significant toxicity attributable to GM-CSF was encountered, the dose was reduced by 50% (5 patients). Toxicities requiring dose modification included persistent fever greater than 101°F in the absence of documented infection, weight gain greater than 5 kg despite the use of diuretics, severe bone pain requiring narcotics for pain relief, or development of pericarditis.
CR was defined as absence of monoclonal gammopathy in serum and urine immunofixation studies and less than 0.1% monoclonal plasma cells in the BM on flow cytometric analysis of DNA and cytoplasmic Ig using monoclonal light chain antibodies.ls Partial remission (PR) required 2 75% tumor cytoreduction with decrease in monoclonal marrow plasmacytosis under 5% and disappearance of Bence Jone proteinuria. No new lytic bone lesions or soft tissue plasmacytoma lesions could appear, whereas the development of compression fractures per se was no indication of disease progression. These criteria had to apply for at least 2 months.
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RESULTS
Three of the 75 patients did not have PBSC collection (persistent thrombocytopenia, 1; refusal, 2; Table 2 ). Of the remaining 72 patients, 2 died before transplantation (disease progression, infection); 1 received an allogeneic BM transplant (BMT) from a matched sibling Patient flow. Seven of the initial 75 patients were in CR before receiving HD-CTX. Eighteen additional patients achieved PR and 2 more CR ( Table 3) . Six of seven patients in CR before HD-CTX and two additional patients achieving CR after HD-CTX continue in CR after transplantation. Of the remaining 52 patients with evaluable disease, 4 achieved CR and 33 PR for an overall response rate of 71% (Table 3) . Considering all 75 patients entered on study, the objective response rate increased from 9% to 35% after HD-CTX (one treatment-related death counted as failure) and to 68% after transplant (includes 1 CR after allogeneic transplant). Estimated rates of 1-year event-free survival (EFS; defined by absence of clinical progression or death) and of overall survival for all 75 patients were 80% and 88%, respectively (Fig 1) . Sixty-three patients (84%) remain alive with a median follow-up time of 12 months (range, 6 to 24).
Responses ( 2 75% tumor regression) occurred more frequently and complete remissions solely among patients with less prior chemotherapy exposure (Table 4) . For HD-CTX, the additional presence of responsiveness to prior standard-dose chemotherapy identified a group of 18 patients with a response rate of 61% (including the only 2 CRs) as opposed to 18% among the remaining 49 patients.
The median time to hematologic recovery was 16 days for both neutrophils ( > 500/pL) and platelets (> 50,0001pL) (range, 10 to 52 days and 9 to 61 days, respectively) ( Table 5 ). With GM-CSF, these blood count levels were reached after a median of 15 days, compared with 18 days without GM-CSF. More than 12 months of prior chemotherapy delayed platelet recovery from a median of 15 to 18 days. With more than 1 year of prior therapy and in the absence of GM-CSF (25 patients), granulocyte and platelet recoveries were delayed by 3 to 5 days, compared with the remaining patients in whom these two adverse parameters were not jointly present (Table 5 ). This observation pertained to all patients, regardless of their responsiveness to prior chemotherapy (data not shown).
PBSC procurement. Seventy-two patients underwent stem cell apheresis. Maximum numbers of CFU-GM colonies per lo5 MNC and highest percentage of CD34+ cells were noted during the first 2 to 3 days of stem cell collection followed by a rapid decline (example shown in Fig 2) . Forty
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Hematologic recovery post-HD-CTX. to have "poor" PBSC mobilization. In comparison to patients with "good" PBSC mobilization, there was a median delay by 5 days to recover similar blood counts and to initiate apheresis among the patients with "poor" mobilization (P < .001). Although the median number of aphereses performed (7 v 8) and of mononuclear cells collected (7.0 x lo8 v 6.7 x 10s/kg bw) were similar for the two groups, the total number of CFU-GM per kilogram of bw was significantly higher in patients with "good" compared with those with "poor" PBSC mobilization (3.8 x lo5 v
Factors favoring "good" stem cell mobilization included less than 12 months of prior chemotherapy exposure and GM-CSF administration (Table 6 ). The combined information on duration of prior therapy and use of GM-CSF helped define three groups of patients with high, intermediate, or low incidence of adequate blood stem cell procurement. Therefore, with less prior therapy and using GM-CSF, 94% of patients had "good" stem cell mobilization. This compared with 58% of those with one and 36% with both unfavorable features. Age did not influence stem cell mobilization. Another feature associated with PBSC procurement was the speed of platelet recovery post-HD-CTX; 85% of those with rapid platelet recovery in 2 weeks had "good" mobilization, compared with 24% of patients with delayed recovery (Table 6) .
Because GM-CSF was administered on the basis of availability rather than in a randomized fashion, the characteristics of patients receiving or not receiving GM-CSF were compared. The two groups were virtually identical with regard to age greater than 50 years (51% v 49%), chemotherapy resistance (45% v 55%), and more than 12 months of prior therapy (44% v 56%).
Autologous marrow was harvested in 67 patients; 5 had persistent marrow plasmacytosis greater than 30%. While equivalent quantities of BM MNC were harvested (median, 2.1 v 2.0 x los MNC/kg bw), the median marrow CFU-GM quantities per kilogram of bw was higher among the patients with "good" versus those with "poor" PBSC mobilization (3 x 104v 1.2 x 104; P < .0001).
Hematologic recovery posttransplantation. The median number of marrow stem cells infused was 2.09 X los MNC/kg bw and the median quantity of CFU-GM infused was 1.3 x lo4 colonies/kg bw; the corresponding values for PBSC were 3.3 x lo8 MNC/kg bw and 5.5 x 104 CFU-GM/kg bw. Three patients received only blood stem cells (median, 10.2 x los MNCikg bw). After transplantation, the median times to recover neutrophils greater than 500/pL and platelets greater than 50,OOOikL were 15 days 0.72 x 1 0 5 ;~ < .oil. 
MONTHS FROM THERAPY
(range, 10 to 51 days) and 19 days (range, 10 to 150 days), respectively. Engraftment kinetics were not influenced by BM MNC or CFU-GM content (minimum, 104 coloniedkg bw). However, patients with "good" PBSC mobilization experienced significantly faster granulocyte and, especially, platelet recovery (Table 7) . Fast post-HD-CTX platelet recovery (> 50,00O/yL within 15 days) assured significantly more rapid platelet, but not granulocyte, recovery after transplantation. Both short duration of prior chemotherapy ( 5 12 months) and GM-CSF post-HD-CTX were associated with both faster granulocyte and platelet recovery posttransplant. These two parameters, previously shown to affect recovery post-HD-CTX (Table 5 ) and PBSC mobilization (Table 6) , were also evaluated for their combined impact on posttransplant engraftment (Table 7) . Recovery of both granulocytes and platelets was delayed among the 18 patients with prolonged prior therapy and no GM-CSF with HD-CTX compared with the remaining 42 who had no more than one of those adverse features. Administration of GM-CSF posttransplant accelerated the recovery of neutrophils but not of platelets. These observations pertained both to patients with sensitive and resistant disease.
In addition to shortening the duration of marrow aplasia, the use of combined marrow and blood stem cells with GM-CSF also aimed at achieving complete hematopoietic recovery (neutrophils > 1,500/ pL, platelets > 1OO,OOO/pL, and hemoglobin >10 g% in the absence of blood cell component therapy). Fifty of the 60 patients receiving transplants achieved such complete hematopoietic engraftment at a median of 1 month (range, 0.5 to 9 months); at the end of 3 months from transplantation, two-thirds had achieved complete hematopoietic recovery. Of the 10 patients not achieving complete hematopoietic recovery, 8 had poor PBSC mobilization; conversely, incomplete engraftment was noted among 35% of patients with 'Lpoor'' but in only 5% of those with "good" PBSC mobilization (P = .009). The median duration of prior therapy for the 10 patients failing to engraft was 15 months (8 months of For candidemia (1 patient) ( Table 9 ). The median duration of hospitalization was 19 days. The 37 patients with "good" stem cell mobilization had a median hospital stay of 18 days; contrasting with 24 days among the 23 patients with "poor" stem cell mobilization (P = .006) (Table 10) . Onethird of the patients experienced no severe extramedullary toxicity (grade I11 or IV [ECOG]). Severe mucositis was noted in 23%; nausea and vomiting in 8%; diarrhea in 7%; and transient renal insufficiency in two patients. Five patients had abnormal liver function tests 3 months after MEL-200. Liver biopsies in all five patients showed similar patterns of scattered necrotic hepatocytes with no inflammatory reaction suggestive of drug toxicity. Abnormal liver functions returned to normal in four patients within 2 to 3 months.
alkylating agents) compared with 6 months (3 months of alkylating agents) for the other patients (P < .OOl).
Transfusion requirements were examined according to hematopoietic stem cell reserve ( Table 8 ). The proportion of patients requiring extensive platelet and packed red blood cell support ( > 10 U) was greater in the "poor" compared with the "good" PBSC mobilization category.
After HD-CTX, 43 patients (57%) had febrile episodes during neutropenia requiring hospitalization for intravenous antibiotics; 17 of these patients had documented infection, including bacteremia (14 patients), candidemia (2 patients), and pulmonary aspergillosis (1 patient) ( Table 9) . One patient died from systemic candidiasis after stem cell harvest. Quinton catheter placement resulted in a pneumothorax in one patient while two others developed subclavian venous thrombosis. GM-CSF dose reduction by 50% was required in nine patients and subsequent discontinuation in four patients before completion of stem cell harvest (because of toxicities persisting despite dose reduction).
Toxicities after transplantation included fever of unknown origin (10 patients), bacteremia (16 patients), and
Toxicities.
DISCUSSION
The growing interest in autologous transplantation for MM justifies efforts to improve the efficacy and safety of this a p p r~a c h .~
In a previous trial of 55 patients receiving melphalan at 140 mg/m2 plus TBI 850 cGy with autologous BM support, the median times to granulocyte and platelet recovery were approximately 21 and 28 days, respectively, and hence about 1 week longer than observed in the current study of 60 patients receiving combined BM and blood stem cell support.'* The transplant-related mortality in the TBI study was 11%, including a 36% incidence among patients with resistant relapse. There was only one treatmentrelated death after HD-CTX (2%) and none after transplantation. While formal comparisons are not possible between these two studies, current results show speedier engraftment in the presence of higher CFU-GM quantities present in PBSC grafts, although BM CFU-GM numbers were similar in the two trials.
Other data using blood stem cells collected under steadystate conditions (without HD-CTX and without GM-CSF) in similar patients indicated recovery kinetics as seen with BM a l~n e . '~J~ Hence, results of this study support the For personal use only. on April 14, 2017. by guest www.bloodjournal.org From findings of Gianni et a1 of accelerated granulocyte and also platelet recovery by the use of blood stem cells collected after HD-CTX with GM-CSF compared with marrow alone.16 With adequate blood stem cell quantities, engraftment was faster not only to safe but to normal levels of both platelets and granulocytes. Effective blood stem cell mobilization and hence normal hematopoietic stem cell reserve were correlated with early platelet (but not granulocyte) recovery after HD-CTX, which in turn was associated with rapid platelet recovery after transplant. In the absence of CFU-GM and CD34+ cell data, post-HD-CTX platelet recovery can therefore serve as a reliable indicator of stem cell reserve and function. Adequate blood stem cell mobilization and prompt posttransplant engraftment could also be anticipated when prior treatment exposure had not exceeded 1 year and GM-CSF was used both after HD-CTX and posttransplant. Parameters have thus been defined that are pertinent both to stem cell procurement and engraftment kinetics after transplant. In the presence of less than adequate blood stem cells or substitute features (delayed post-HD-CTX platelet recovery, >12 months of prior therapy, and no GM-CSF), engraftment, especially of platelets, was delayed after transplantation.
Patients receiving MEL-200 can be considered within 3 to 6 months for a second transplant with either the same or an alternative preparative regimen including TBI. With adequate blood stem cell mobilization, complete hematopoietic recovery without mortality can be anticipated also after the second transplant for the majority of patients. 21 Physicians considering autologous transplantation for their MM patients should keep the exposure especially to normal stem cell-damaging agents such as melphalan and nitrosourias to less than 1 year. Under those circumstances, HD-CTX plus GM-CSF can be expected to yield high blood stem cell quantities supporting speedy engraftment at relatively low risk because of brief myelosuppression. However, limited antitumor activity, inconvenience, and potential toxicity associated with HD-CTX warrant clinical trials in MM to determine whether similar results might be obtained with hematopoietic growth factors alone without HD-CTX. It is too early to comment on long-term tumor control obtained with HD-CTX and subsequent MEL-200. Hematopoietic stem cell procurement has been adequate for the conduct of a second transplant within 6 months, which has been safely conducted so far in 35 of the 60 patients receiving transplants in this series. The virtual absence of transplant-related mortality was due in large part to the brief duration of marrow aplasia and the low incidence also of serious extramedullary toxicities in the case of MEL-200 compared with MEL-TBI. EFS and overall survival estimates of almost 90% at 1 year are superior to results obtained previously with MEL-TBI and autologous BMT. Complete hematopoietic recovery even after two transplants assures the possibility of future chemotherapy in the event of relapse posttransplant. Longer follow-up is required to determine whether this favorable outcome is not only due to elimination of treatment-related mortality but sustained antitumor effect as a result of repeated cycles of better tolerated MEL-200.
